Key clinical point: Blocking the complement pathway is a novel method for treating at least one form of hemolytic anemia.
Major finding: Hemoglobin levels increased by a mean of 2.6 g/dL.
Study details: An open-label, phase 3 trial in 24 patients with cold agglutinin disease, a rare autoimmune hemolytic anemia.
Disclosures: The study was supported by Sanofi. Dr. Röth reported financial relationships with Sanofi and other companies.
Röth A et al. ASH 2019, Abstract LBA-2.